Periorbital Photoaging
Conditions
Interventions
Trial group (Brimonidine group):Lidocaine–prilocaine cream with brimonidine
Control Group:Lidocaine–prilocaine cream
Sponsors
The Third Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Male or female subjects of Mongoloid descent (Yellow race), aged between 20 and 40 years; 2. Self-requested improvement of periorbital photoaging, such as periorbital fine lines, periorbital hyperpigmentation (dullness), and periorbital skin laxity; 3. Symmetrical facial target areas for treatment; 4. Capable of understanding and complying with the study requirements and willing to complete all scheduled follow-up visits; 5. Signing of the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Individuals planning for pregnancy, or those who are currently pregnant or lactating; 2. Individuals with hepatic or renal impairment; 3. Individuals with hypersensitivity to amide-type local anesthetics or any components of the compound lidocaine cream; 4. Individuals with hypersensitivity to Brimonidine Tartrate Eye Drops or any of its components; 5. Patients receiving treatment with monoamine oxidase (MAO) inhibitors or antidepressants that affect noradrenergic transmission; 6. Patients with congenital or idiopathic methemoglobinemia; 7. Patients with syndromes associated with vascular insufficiency, including cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, or severe cardiovascular malformations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score (VAS, Visual Analog Scale); | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythema Score;Efficacy assessment;Patient satisfaction;Edema Score; | — |
Countries
China
Contacts
Public ContactLi Xueqing
The Third Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed